Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02425683 · ClinicalTrials.gov registry record · Phase 2
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
A Phase 2 study, sponsored by US Oncology Research.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02425683 is a Phase 2 study that was terminated before completion, run by US Oncology Research. The registered enrollment target is 24 participants.
The verdict
NCT02425683, a Phase 2 study, was terminated before completion, sponsored by US Oncology Research.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study, for patients who have Stage IIIC colorectal cancer and who underwent 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) chemotherapy after surgery, will test to see if regorafenib given after the completion of FOLFOX improves treatment, compared to standard of care (SOC), which is no further treatment.
Interventions
- DRUG Regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-03-26 |
| Est. Completion | 2017-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02425683
The ClinicalTrials.gov registry entry for NCT02425683 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Regorafenib is the first listed.
NCT02425683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02425683 about?
NCT02425683 is a clinical study titled "Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX". This study, for patients who have Stage IIIC colorectal cancer and who underwent 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) chemotherapy after surgery, will test to see if regorafenib given after the completion of FOLFOX improves treatment, compared to standard of care (SOC), which is no fu...
What is the current status of trial NCT02425683?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2015-03-26. Estimated completion is 2017-09-21.
What interventions are being tested in trial NCT02425683?
The interventions under investigation include: Regorafenib (DRUG).
Who is sponsoring clinical trial NCT02425683?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.